Cerus EBITDA 2010-2024 | CERS
Cerus ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
| Cerus Annual EBITDA (Millions of US $) |
|
|---|---|
| 2023 | $-27 |
| 2022 | $-31 |
| 2021 | $-46 |
| 2020 | $-55 |
| 2019 | $-64 |
| 2018 | $-54 |
| 2017 | $-56 |
| 2016 | $-60 |
| 2015 | $-59 |
| 2014 | $-43 |
| 2013 | $-28 |
| 2012 | $-17 |
| 2011 | $-15 |
| 2010 | $-15 |
| 2009 | $-23 |
| Cerus Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-1 |
| 2024-06-30 | $-3 |
| 2024-03-31 | $-7 |
| 2023-12-31 | $2 |
| 2023-09-30 | $-5 |
| 2023-06-30 | $-11 |
| 2023-03-31 | $-14 |
| 2022-12-31 | $-9 |
| 2022-09-30 | $-7 |
| 2022-06-30 | $-6 |
| 2022-03-31 | $-9 |
| 2021-12-31 | $-6 |
| 2021-09-30 | $-10 |
| 2021-06-30 | $-14 |
| 2021-03-31 | $-16 |
| 2020-12-31 | $-14 |
| 2020-09-30 | $-13 |
| 2020-06-30 | $-14 |
| 2020-03-31 | $-15 |
| 2019-12-31 | $-16 |
| 2019-09-30 | $-16 |
| 2019-06-30 | $-16 |
| 2019-03-31 | $-16 |
| 2018-12-31 | $-15 |
| 2018-09-30 | $-13 |
| 2018-06-30 | $-12 |
| 2018-03-31 | $-13 |
| 2017-12-31 | $-10 |
| 2017-09-30 | $-12 |
| 2017-06-30 | $-16 |
| 2017-03-31 | $-18 |
| 2016-12-31 | $-15 |
| 2016-09-30 | $-14 |
| 2016-06-30 | $-16 |
| 2016-03-31 | $-15 |
| 2015-12-31 | $-15 |
| 2015-09-30 | $-16 |
| 2015-06-30 | $-15 |
| 2015-03-31 | $-14 |
| 2014-12-31 | $-13 |
| 2014-09-30 | $-11 |
| 2014-06-30 | $-11 |
| 2014-03-31 | $-9 |
| 2013-12-31 | $-7 |
| 2013-09-30 | $-8 |
| 2013-06-30 | $-7 |
| 2013-03-31 | $-5 |
| 2012-12-31 | $-3 |
| 2012-09-30 | $-4 |
| 2012-06-30 | $-5 |
| 2012-03-31 | $-4 |
| 2011-12-31 | $-3 |
| 2011-09-30 | $-3 |
| 2011-06-30 | $-5 |
| 2011-03-31 | $-4 |
| 2010-12-31 | $-4 |
| 2010-09-30 | $-3 |
| 2010-06-30 | $-3 |
| 2010-03-31 | $-4 |
| 2009-12-31 | $-5 |
| 2009-09-30 | $-6 |
| 2009-06-30 | $-5 |
| 2009-03-31 | $-7 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.293B | $0.156B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $198.127B | 25.27 |
| Stryker (SYK) | United States | $138.991B | 31.32 |
| Boston Scientific (BSX) | United States | $131.097B | 37.69 |
| EssilorLuxottica (ESLOY) | France | $109.895B | 0.00 |
| Medtronic (MDT) | Ireland | $103.904B | 15.43 |
| Haleon (HLN) | United Kingdom | $43.864B | 28.50 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.859B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $36.052B | 18.70 |
| ResMed (RMD) | United States | $34.830B | 28.62 |
| Terumo (TRUMY) | Japan | $28.875B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.602B | 18.07 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.325B | 13.58 |
| Insulet (PODD) | United States | $18.698B | 74.46 |
| Baxter (BAX) | United States | $15.062B | 9.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.781B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.800B | 39.43 |
| Bio-Rad Laboratories (BIO) | United States | $9.168B | 31.16 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.208B | 14.42 |
| Prestige Consumer Healthcare (PBH) | United States | $3.889B | 19.34 |
| ICU Medical (ICUI) | United States | $3.840B | 36.56 |
| Haemonetics (HAE) | United States | $3.789B | 18.49 |
| Perrigo (PRGO) | Ireland | $3.513B | 10.34 |
| Envista Holdings (NVST) | United States | $3.218B | 23.97 |
| QuidelOrtho (QDEL) | United States | $3.016B | 19.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.609B | 30.10 |
| LeMaitre Vascular (LMAT) | United States | $2.071B | 50.34 |
| Green Thumb Industries (GTBIF) | United States | $1.678B | 29.37 |
| AtriCure (ATRC) | United States | $1.498B | 0.00 |
| InMode (INMD) | Israel | $1.434B | 8.63 |
| AdaptHealth (AHCO) | United States | $1.383B | 9.88 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.356B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.271B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.968B | 0.00 |
| Owens & Minor (OMI) | United States | $0.965B | 7.54 |
| CeriBell (CBLL) | United States | $0.964B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.879B | 15.49 |
| Evolus (EOLS) | United States | $0.690B | 0.00 |
| Omeros (OMER) | United States | $0.597B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.594B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.584B | 25.75 |
| Surmodics (SRDX) | United States | $0.568B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.452B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.439B | 0.00 |
| Quanterix (QTRX) | United States | $0.403B | 0.00 |
| ZimVie (ZIMV) | United States | $0.375B | 31.63 |
| Biote (BTMD) | United States | $0.331B | 7.26 |
| Valneva SE (VALN) | France | $0.324B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.311B | 29.56 |
| Canopy Growth (CGC) | Canada | $0.308B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.294B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.20 |
| Zynex (ZYXI) | United States | $0.263B | 55.00 |
| High Tide (HITI) | Canada | $0.242B | 100.33 |
| Aurora Cannabis (ACB) | Canada | $0.234B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.29 |
| Sanuwave Health (SNWV) | United States | $0.201B | 2.82 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.197B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.190B | 0.00 |
| Brainsway (BWAY) | Israel | $0.174B | 92.40 |
| FitLife Brands (FTLF) | United States | $0.145B | 18.17 |
| Jin Medical (ZJYL) | China | $0.133B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.107B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.81 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| Veru (VERU) | United States | $0.095B | 0.00 |
| Exagen (XGN) | United States | $0.091B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.044B | 0.00 |
| ImmuCell (ICCC) | United States | $0.039B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.74 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |